Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17421860 | 1.00 | THRB (0.32) | THRB | |
| Boric Acid SCHEMBL29096575 | 0.80 | THRB (0.32) | THRB | |
| Boric Acid SCHEMBL28861877 | 0.80 | THRB (0.32) | THRB | |
| SCHEMBL127444 | 0.78 | — | — | |
| Boric Acid SCHEMBL27938813 | 0.74 | THRB (0.38) | THRB | |
| Boric Acid SCHEMBL474845 | 0.73 | THRB (0.43) | THRB | |
| Boric Acid SCHEMBL4976220 | 0.73 | THRB (0.43) | THRB | |
| Boric Acid SCHEMBL28285073 | 0.73 | THRB (0.43) | THRB | |
| Boric Acid SCHEMBL4139673 | 0.73 | THRB (0.43) | THRB | |
| Boric Acid SCHEMBL594481 | 0.73 | THRB (0.43) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630564-B2 | Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| WO-2026089784-A2 | COMPOUNDS AND COMPOSITIONS FOR CONJUGATION TO BIOLIGANDS FOR IMAGING AND RADIOPHARMACEUTICAL APPLICATIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4713020-A2 | DRUG-LINKERS AND DRUG CONJUGATES | Solve Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | PI INDUSTRIES LTD. (IN) | 2026-03-17 | — | — | US | disclosed |
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-4056570-B1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | KEYMED BIOSCIENCES (CHENGDU) CO., LTD. (CN) | 2026-01-01 | — | — | US | disclosed |
| EP-4623936-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | Keymed Biosciences (Chengdu) Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250223303-A1 | TRICYCLIC BORONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-8710060-B2 | Piperazinyl methyl phenyl cyclohexane compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-29 | — | — | US | disclosed |
| WO-2014018765-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20130289048-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-10-31 | — | — | US | disclosed |
| EP-2623492-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-07 | — | — | EP | disclosed |
| EP-2595958-A2 | NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID {3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL}-AMIDE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022258-A1 | Novel Processes for the manufacture of Propane-1-sulfonic acid -amide | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010538-A2 | NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID {3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL}-AMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| US-20100274058-A1 | Process for Preparation of 2-[Vinyl (Hetero) Arylsulphonyl] Ethanol Derivatives | UNIVERSITY OF DURHAM (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-1989181-A1 | PROCESS FOR THE PREPARATION OF 2-[VINYL (HETERO) ARYL SULPHONYL]ETHANOL DERIVATIVES | UNIVERSITY OF DURHAM (GB) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007093772-A1 | PROCESS FOR THE PREPARATION OF 2- [VINYL (HETERO) ARYL SULPHONYL] ETHANOL DERIVATIVES | UNIVERSITY OF DURHAM (GB) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | HSD11B1, CYP4A11, CYP8B1 | THRB 1901/4885 |
| US-20100274058-A1 | Process for Preparation of 2-[Vinyl (Hetero) Arylsulphonyl] Ethanol Derivatives | SMARCC2, SMARCC1, PYM1 | THRB 1101/4885 |
| US-20250223303-A1 | TRICYCLIC BORONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CYP51A1, SLC10A2, BCAT2 | THRB 712/4885 |
| US-12630564-B2 | Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis B | HCCS, SLC10A1, NR1H4 | THRB 372/4885 |
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | THRB 394/4885 |
| US-20120022258-A1 | Novel Processes for the manufacture of Propane-1-sulfonic acid -amide | SULT1A1, FASN, COASY | THRB 4078/4885 |
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | THRB 236/4885 |
| US-20130289048-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | HRH2, CBR1, HRH4 | THRB 1988/4885 |
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | SULT1E1, CBR1, SULT1A1 | THRB 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.